AU2001262684A1 - Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity - Google Patents

Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity

Info

Publication number
AU2001262684A1
AU2001262684A1 AU2001262684A AU6268401A AU2001262684A1 AU 2001262684 A1 AU2001262684 A1 AU 2001262684A1 AU 2001262684 A AU2001262684 A AU 2001262684A AU 6268401 A AU6268401 A AU 6268401A AU 2001262684 A1 AU2001262684 A1 AU 2001262684A1
Authority
AU
Australia
Prior art keywords
pseudo
vector containing
membrane protein
retrovirus vector
containing membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001262684A
Inventor
Mamoru Hasegawa
Akihiro Iida
Masanori Kobayashi
Toshihiro Nakajima
Kenji Nakamaru
Hiroyuki Sakakibara
Yasuji Ueda
Yoshikazu Yonemitsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dnavec Research Inc
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Publication of AU2001262684A1 publication Critical patent/AU2001262684A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001262684A 2000-06-01 2001-06-01 Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity Abandoned AU2001262684A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-169090 2000-06-01
JP2000169090 2000-06-01
PCT/JP2001/004659 WO2001092508A1 (en) 2000-06-01 2001-06-01 Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity

Publications (1)

Publication Number Publication Date
AU2001262684A1 true AU2001262684A1 (en) 2001-12-11

Family

ID=18672001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001262684A Abandoned AU2001262684A1 (en) 2000-06-01 2001-06-01 Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity

Country Status (10)

Country Link
US (1) US7510706B2 (en)
EP (1) EP1291419B1 (en)
JP (1) JP4700888B2 (en)
KR (1) KR100807016B1 (en)
CN (1) CN100531802C (en)
AU (1) AU2001262684A1 (en)
CA (1) CA2413995C (en)
ES (1) ES2430991T3 (en)
HK (1) HK1056576A1 (en)
WO (1) WO2001092508A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
JP3748535B2 (en) * 1999-09-06 2006-02-22 株式会社ディナベック研究所 Paramyxovirus with altered transcription initiation sequence
US7314614B1 (en) 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
EP1251174A4 (en) * 2000-01-19 2003-05-02 Dnavec Research Inc Use of paramyxovirus vector in gene transfer into blood vessel
KR100854917B1 (en) * 2000-03-30 2008-08-27 가부시키가이샤 디나벡크 겐큐쇼 AIDS virus vaccines using sendai virus vector
WO2002000264A1 (en) * 2000-06-27 2002-01-03 Dnavec Research Inc. Virus vector for transferring gene into renal cells
US20040053877A1 (en) * 2000-10-06 2004-03-18 Masayuki Fukumura Paramyxovirus vector for transfering foreign gene into skeletal muscle
JP2002142770A (en) * 2000-11-08 2002-05-21 Dnavec Research Inc Paramyxovirus vector for transporting gene to circulatory system
KR100812884B1 (en) 2000-11-27 2008-03-11 가부시키가이샤 디나벡크 겐큐쇼 Paramyxovirus vector encoding angiogenesis gene and use thereof
GB0202569D0 (en) * 2002-02-04 2002-03-20 Oxford Biomedica Ltd Delivery means
JPWO2003092738A1 (en) * 2002-04-30 2005-09-08 株式会社ディナベック研究所 Drug or gene delivery composition with reduced hemagglutinin activity
EP1548101A4 (en) * 2002-09-04 2006-05-10 Dnavec Research Inc Methods of producing a viral vector comprising a membrane protein that binds to sialic acid as a component of the envelope using neuraminidase derived from gram-positive bacteria
EP1398041A1 (en) * 2002-09-13 2004-03-17 Université de Nantes Recombinant lentiviral vector pseudotyped with the hemagglutinin protein for gene transfer into the retina
US20060104950A1 (en) * 2002-10-24 2006-05-18 Shinji Okano Methods of Tranducing genes into T cells
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
US20050164384A1 (en) * 2003-04-04 2005-07-28 Greene Lloyd A. Methods for regulating differentiation of neural cells and uses thereof
US8158420B2 (en) * 2003-04-04 2012-04-17 The Trustees Of Columbia University In The City Of New York Methods for inhibiting the differentation of proliferative telencephalic cells in vitro by addition of ATF5
US20070105208A1 (en) * 2003-06-30 2007-05-10 Jun You Minus strand rna virus vector carrying gene modified in high mutation region
US20070141705A1 (en) * 2004-01-22 2007-06-21 Makoto Inoue Method for producing viral vectors
WO2005087936A1 (en) * 2004-03-16 2005-09-22 Dnavec Research Inc. Method of transferring gene into embryonic stem cell
WO2006090689A1 (en) * 2005-02-23 2006-08-31 Dnavec Corporation Remedy for disease associated with apoptotic degeneration in ocular cell tissue with the use of siv-pedf vector
EP2993235B1 (en) * 2005-10-28 2019-02-13 ID Pharma Co., Ltd. Gene transfer into airway epithelial stem cell by using simian lentiviral vector pseudotyped with sendai rna virus spike protein
CA2541872A1 (en) * 2006-04-26 2007-10-26 Institut Pasteur H5 pseudotyped viruses and uses thereof
EP1975239A1 (en) 2006-09-27 2008-10-01 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
ES2708856T3 (en) * 2007-08-03 2019-04-11 Pasteur Institut Vectors of lentiviral gene transfer and its medicinal applications
ES2617749T3 (en) * 2010-01-08 2017-06-19 Immusoft Corporation Vectors and procedures for transduction of B lymphocytes
JP6439690B2 (en) * 2013-07-12 2018-12-19 石原産業株式会社 Composition for gene transfer into cells
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
CA3080424A1 (en) * 2017-10-30 2019-05-09 Miltenyi Biotec B.V. & Co. KG Adapter-based retroviral vector system for the selective transduction of target cells
GB202105276D0 (en) * 2021-04-13 2021-05-26 Imperial College Innovations Ltd Delivery of gene therapy vectors
GB202105278D0 (en) * 2021-04-13 2021-05-26 Imperial College Innovations Ltd Cell therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634904T2 (en) * 1995-10-31 2006-05-18 Dnavec Research Inc., Tsukuba NEGATIVE STONE RNA VIRUS WITH SELF-ACTIVE REPLICATION ACTIVITY
ATE470704T1 (en) * 1995-11-01 2010-06-15 Dnavec Research Inc RECOMBINANT SENDAI VIRUS
EP1484409B1 (en) * 1996-12-16 2009-04-08 Eisai R&D Management Co., Ltd. DNA-construction comprising a drug-resistance gene and a foreign gene
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
AU9399498A (en) * 1997-09-18 1999-04-05 Trustees Of The University Of Pennsylvania, The Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US6828138B1 (en) * 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
JP3748535B2 (en) * 1999-09-06 2006-02-22 株式会社ディナベック研究所 Paramyxovirus with altered transcription initiation sequence
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
EP1251174A4 (en) * 2000-01-19 2003-05-02 Dnavec Research Inc Use of paramyxovirus vector in gene transfer into blood vessel
KR100854917B1 (en) * 2000-03-30 2008-08-27 가부시키가이샤 디나벡크 겐큐쇼 AIDS virus vaccines using sendai virus vector
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
WO2002000264A1 (en) * 2000-06-27 2002-01-03 Dnavec Research Inc. Virus vector for transferring gene into renal cells
US20040053877A1 (en) * 2000-10-06 2004-03-18 Masayuki Fukumura Paramyxovirus vector for transfering foreign gene into skeletal muscle
JP2002142770A (en) * 2000-11-08 2002-05-21 Dnavec Research Inc Paramyxovirus vector for transporting gene to circulatory system
KR100812884B1 (en) * 2000-11-27 2008-03-11 가부시키가이샤 디나벡크 겐큐쇼 Paramyxovirus vector encoding angiogenesis gene and use thereof
GB0202569D0 (en) 2002-02-04 2002-03-20 Oxford Biomedica Ltd Delivery means
EP1548101A4 (en) 2002-09-04 2006-05-10 Dnavec Research Inc Methods of producing a viral vector comprising a membrane protein that binds to sialic acid as a component of the envelope using neuraminidase derived from gram-positive bacteria

Also Published As

Publication number Publication date
JP4700888B2 (en) 2011-06-15
ES2430991T3 (en) 2013-11-22
HK1056576A1 (en) 2004-02-20
CN100531802C (en) 2009-08-26
CA2413995A1 (en) 2002-12-02
CN1444650A (en) 2003-09-24
CA2413995C (en) 2013-08-13
EP1291419A1 (en) 2003-03-12
KR100807016B1 (en) 2008-02-25
EP1291419A4 (en) 2004-09-08
US20030203489A1 (en) 2003-10-30
WO2001092508A1 (en) 2001-12-06
KR20030074115A (en) 2003-09-19
US7510706B2 (en) 2009-03-31
EP1291419B1 (en) 2013-09-18

Similar Documents

Publication Publication Date Title
AU2001262684A1 (en) Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity
AU2001273164A1 (en) Membrane associated protein zupari
AU6906800A (en) Membrane associated proteins
AU2001234981A1 (en) Adenoviral capsid containing chimeric protein ix
AU2003242713A1 (en) Complex coacervates containing whey proteins
AU2002337815A1 (en) Active agents using liposome beads
AU4012100A (en) Pseudotyped lentiviral vectors and uses thereof
AU2001276692A1 (en) Modified hollow-fiber membrane
AU3225700A (en) Preparation of polyethersulfone membranes
AU2495300A (en) Lentivirus vector system
AU3916400A (en) Human transmembrane proteins
AU2002232707A1 (en) Transmembrane proteins
AU2001232219A1 (en) Protein monitoring the activity of small gtp-binding protein
AU5032501A (en) Use of cationic protein hydrolysates
AU2002358756A1 (en) Sequencing on perforated membranes
AU4352000A (en) Clasp-2 transmembrane proteins
AU2001265190A1 (en) Siv derived lentiviral vector systems
AU6050098A (en) Human integral membrane protein
AU2002224379A1 (en) Clasp-2 transmembrane proteins
AU2003237374A1 (en) Improved pseudotyped retroviruses
AU3774000A (en) Conformationally constrained peptides
AU2001255501A1 (en) Blood-pressure reducing polypeptides containing vpp derived from microorganisms
AU3151999A (en) Peptide ligand having specific affinity for the hiv1 retrovirus p24 protein
AU2001278975A1 (en) Alpha-conotoxin peptides
AU2269701A (en) Clasp-4 transmembrane protein